Lingering Lymphocytes Lash Out Against Leishmania

Article

Immune cells that hang around after parasitic skin infection help ward off secondary attack, according to a study in the Journal of Experimental Medicine. These skin squatters may prove to be the key to successful anti-parasite vaccines.

Glennie et al. show that memory CD4+ T cells (green) in the skin reduce the number of parasites after secondary Leishmania infection by recruiting parasite-fighting memory CD4+ T cells (red). Image courtesy of Rockefeller University Press
 
Immune cells that hang around after parasitic skin infection help ward off secondary attack, according to a study in the Journal of Experimental Medicine. These skin squatters may prove to be the key to successful anti-parasite vaccines.

Leishmania are a group of parasites that are transmitted by sandflies and cause a variety of diseases, including an ulcerative skin disease. Successful clearance of Leishmania infection results in long-lasting immunity to reinfection. This protection relies in part on circulating immune cell called memory CD4+ T cells, which recall the initial infection and respond with increased rapidity and vigor. But the protection provided by transferring these memory cells into uninfected mice pales in comparison to that conferred by prior infection, suggesting the involvement of other cells or pathways.

Phillip Scott and his colleagues at the University of Pennsylvania now show that circulating memory CD4+ T cells rely on a little help from skin-resident friends. The group found that some of the Leishmania-fighting CD4+ T cells that help fend off initial infections in mice linger in the skin for up to a year after the infection resolves. These skin-resident memory cells reduced the number of parasites in the skin during secondary infection, largely due to their ability to attract parasite-fighting memory CD4+ T cells from the blood. Invoking the dual action of skin and blood memory CD4+ T cells may be the key to developing an effective anti-Leishmania vaccine for humans, which has thus far been elusive.

Reference: Glennie ND, et al. 2015. J. Exp. Med. doi:10.1084/jem.20142101

Source: Journal of Experimental Medicine/Rockefeller University Press

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content